Published in Cancer Weekly, August 31st, 2004
Clinton Howard, CEO stated, "The improvement in earnings during the second quarter continues a favorable trend from the first quarter. Earnings for the first 6 months of this year were $222,000, or $.01 per share, compared to a loss of $34,000 in the first half of last year. We attribute this improvement mainly to expense reductions that resulted from restructuring operations during 2003."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.